Across TCGA pan-cancer cohorts, CALY Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CALY data layer compared with 26 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CALY Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CALY expression acts as an unfavorable survival marker.
BLCA and DLBC are the cancer types where CALY Mutation most reproducibly stratifies survival.